What is Spry Therapeutics?
Spry Therapeutics operates at the intersection of clinical innovation and consumer wellness, leveraging patented technologies to redefine standards in patient positioning and infection control. By developing clinically-proven PPE solutions and virus-blocking systems, the company addresses critical gaps in both hospital and hospitality environments. Their market position is defined by a commitment to improving clinical outcomes through affordable, high-impact hardware. As the healthcare sector increasingly prioritizes preventative care and recovery efficiency, Spry Therapeutics serves as a pivotal player in the medical technology landscape, bridging the gap between institutional-grade safety and everyday comfort.
How much funding has Spry Therapeutics raised?
Spry Therapeutics has raised a total of $15M across 1 funding round:
Other Financing Round
$15M
Other Financing Round (2024): $15M with participation from F-Prime Capital Partners, Together Fund Development, Flourish, and Fidelity
Key Investors in Spry Therapeutics
F-Prime Capital Partners
A venture capital firm with a deep bench of doctors and scientists, specializing in high-growth healthcare and technology investments.
Together Fund Development
A boutique firm focused on grant writing and strategic fund development for tax-exempt organizations and small businesses.
Flourish
A global venture capital firm that supports mission-driven entrepreneurs with a focus on fintech and systemic financial empowerment.
What's next for Spry Therapeutics?
With this major enterprise-level funding, Spry Therapeutics is poised to scale its manufacturing capabilities and expand its distribution network. The strategic allocation of this capital will likely focus on deepening R&D efforts for its next generation of recovery solutions and enhancing its market penetration within the healthcare industry. By leveraging the expertise of its diverse investor base, the company is expected to transition from a specialized innovator to a broader market leader, focusing on sustainable growth and the commercialization of its core intellectual property. Future initiatives will likely prioritize the integration of its virus-blocking technology into larger-scale institutional settings, further solidifying its footprint in the global health-tech ecosystem.
See full Spry Therapeutics company page
